The Quantum Blue® rapid test combines the ease and speed of lateral flow technology (using a highly specific monoclonal antibody), with full quantification by means of a small, telephone sized reading device. The Quantum Blue® 3rd generation reader analyzes line intensities by state of the art image analysis and translates them into a quantitative result within minutes and is ideal to obtain test results fast and speed up the clinical decision. Besides calprotectin, BÜHLMANN offers the possibility for therapeutic drug monitoring (TDM) on the Quantum Blue® reader.

If you are looking for information on our older 2nd generation of the Quantum Blue® Reader, please visit this page.

The inflammation typical in Ulcerative Colitis and Crohn’s Disease is not present in IBS. It is thought that IBS affects over 30 million people in Europe and results in over 2 million visits annually to physicians. Fecal calprotectin is the ideal tool to differentiate IBS from IBD and to avoid unnecessary invasive diagnostic procedures.

The clinical course of most patients with IBD is marked by periods of remission with intermittent relapses characterized by increased intestinal inflammation. Numerous published studies by Tibble et al. and others, have studied the levels of calprotectin in patients during the course of the disease. The results show that calprotectin is a good predictor of relapse in patients with IBD, thus giving clinicians an effective tool to adapt the patients treatment accordingly and to ease the relapse severity.

Click here for more information on the Quantum Blue® calprotectin products.


BÜHLMANN has launched the first rapid test for therapeutic drug monitoring (TDM) in the market. The Quantum Blue® Adalimumab and the Quantum Blue® Infliximab assays offer trough level quantification of serum drug levels within 15 minutes. The tests use highly specific monoclonal antibodies and show a very high correlation to common ELISA assays.The Quantum Blue® Infliximab assay now also allows the detection of anti-drug antibodies (ADA) against Infliximab.

Click here for more information on the Quantum Blue® Adalimumab assay.
Click here for more information on the Quantum Blue® Anti-Adalimumab assay.
Click here for more information on the Quantum Blue® Infliximab assay.
Click here for more information on the Quantum Blue® Anti-Infliximab assay.

Watch Tutorial Videos on YouTube

Quantum Blue® Reader Flyer, User Manual, Connect Software and Quick Guides